Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
Market Analysis and Company Profiles Including Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson and Other Companies in the US, Europe, Israel, India, Canada and South Korea, Exploring those Diagnostic Products for Personalised Medicine and Partnerships with Pharmaceutical Developers
Companion Diagnostics – Discover Leading Companies’ Activities and Outlooks How are companies in the companion diagnostics (CDx) industry performing? Visiongain’s new report gives you data, analysis and discussions for producers of those medical devices.
Our study lets you assess top companies in that industry and market, showing you their activities and outlooks. There you see financial results, opinion, trends, opportunities and revenue prediction for those developments in biomarkers, genomics, targeted therapies, theranostics and personalised medicine.
That way you explore the potentials of established and rising companies. Please read on to scan those 17 leading competitors and see what their future market could be worth.
Forecasts and discussions to help you stay ahead in knowledge and authority Our new study assesses 17 leading companies and analyses that overall market. There you find sales results, revenue forecasting and growth rates. In our 166 page report you get 34 tables, 23 charts and an interview with MedGenome.
You also gain qualitative analyses, including discussion of research and development. Our work lets you assess the most beneficial and lucrative applications of those diagnostic tests for advancing human medicine, making it more personalised. Discover what is happening.
Company profiles – see why firms succeed, also exploring their potentials Our report profiles 17 leading companies worldwide. Our investigation discusses prominent companies, exploring their activities by: • Analysing companion diagnostic product portfolios and technologies • Investigating the status of commercial developments • Assessing R&D and applications for those medical devices • Uncovering organisations’ strengths, weaknesses, activities, strategies and prospects • Giving qualitative analyses and revenue forecasting of the overall world companion diagnostics market from 2016 to 2026.
Our survey shows you how technology changes, as well as explaining how diagnostic needs develop from 2016. Assess the rising demand for companion diagnostic products.
Prospects for US-based developers, manufacturers and marketers Chapter 4 profiles companion diagnostic manufacturers based in the United States. Leading companies profiled there are these seven organisations: • Abbott Laboratories • Myriad Genetics • Genomic Health • Thermo Fisher Scientific • Johnson & Johnson • LabCorp • Illumina.
There you discover what the future holds, seeing how companies compare and compete. Suppliers and users of companion diagnostic systems will benefit from 2016.
Outlooks for European manufacturers of those diagnostic medical devices Chapter 5 profiles companion diagnostic manufacturers based in Europe. Leading companies profiled there are these six firms: • Roche • Qiagen • Agilent Technologies • bioMérieux • Siemens • MDxHealth.
Many opportunities remain, with expanding revenues likely from 2016 to 2026. Discover what is possible, seeing how you could gain.
Potentials of developers and producers in the rest of the world Chapter 6 profiles companion diagnostic manufacturers based in the rest of the world. Leading companies profiled there are these four organisations: • MedGenome • Diagnocure • Seegene • Savyon Diagnostics.
Our work shows you possibilities for improving those technologies and raising sales, harnessing biopharmaceuticals, gene technologies and targeted therapies, including personalised medicine. See what the present and future hold, finding how you could gain.
Forces affecting the companion diagnostics industry – what shapes its present and future? Our report discusses pressures, opportunities and other events affecting that industry and market from 2016, including these influences: • Biomarker discovery and technologies including genomics, pharmacogenomics, proteomics and metabolomics • Laboratory developed tests (LDT) • Theranostics – the fastest growing segment of the CDx market • Partnerships and other deals, including M&A and collaborations with pharma companies including Eli Lilly, AstraZeneca, Merck, GSK, Pfizer and Novartis • Applications in cancer therapy and other therapeutic fields • Regulations for companion diagnostic tests – opportunities and challenges.
With our analysis you assess that industry’s strengths, weaknesses, opportunities and threats. See what is happening and how to gain. That way you explore what restricts and stimulates companies developing, producing, marketing and selling those diagnostic tools.
Value of that market in 2020 – what sales growth is possible? Our investigation predicts overall world revenues for companion diagnostic tests will reach $10.52bn in 2020. Those sales will rise further to 2026, showing strong revenue growth. Many opportunities exist for companies large and small as personalised medicine expands.
Ways Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 helps your work In particular our new study gives you this knowledge to benefit your research, analyses, plans and presentations: • Profiles of 17 leading companion diagnostic companies – assess their products, technologies, partnerships, R&D and results • Forecasted revenue to 2026 for that overall market at world level – discover expected sales rises for companion diagnostic products, finding the gains possible • Competition and opportunities – explore what affects that industry, assessing forces influencing its sales and determining its future • Opinion from an interview with a leading company – gain information to help you stay ahead in knowledge, benefiting your reputation for commercial insight.
That new study, by our in-house analysts in the UK, has the purpose of helping your work. There you gain data and discussions you find nowhere else, helping you succeed.
Independent analysis to benefit your authority on companion diagnostics Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where technological and financial prospects are most promising.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could help your research, analyses and decisions, also saving time and benefiting your authority. Explore that industry’s future, seeing what is possible and how you could gain.
Our new investigation is for everyone analysing companion diagnostic tests and associated medical products. There you find data, trends, opportunities and forecasts. Avoid missing out. Instead benefit in knowledge and influence by getting our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the Top Companion Diagnostic Companies 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Industry Survey 1.5 Who is This Study For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2. Introduction to Companion Diagnostics 2.1 Changing Paradigms of Treatment 2.2 What is Personalised Medicine? 2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine 2.3.1 What are In Vitro Diagnostic (IVD) Tests? 2.3.2 How IVDs Help Provide Personalised Treatment 2.4 Companion Diagnostics: Tools for Personalised Medicine 2.4.1 Theranostics: A Subset of Companion Diagnostics 2.5 Biomarkers to Companion Diagnostics 2.5.1 Advancements in Biomarker Discovery 2.5.2 Genomics 2.5.3 Pharmacogenomics 2.5.4 Genomic Biomarkers in Oncology 2.5.5 Proteomics 2.5.6 Metabolomics 2.6 Development of Companion Diagnostics 2.7 Regulations in the Companion Diagnostics Market 2.7.1 FDA’s Draft Guidance on Companion Diagnostics 2.7.1.1 Laboratory Developed Tests (LDT) – A New Direction
3. The World Companion Diagnostics Market, 2016-2026 3.1 The Global Companion Diagnostics Market, 2015 3.2 The Global Companion Diagnostics Market Sales Forecast, 2016-2026 3.3 Companion Diagnostics: Increasing Market Share of the IVD Market 3.4 The Companion Diagnostics Market by Submarket, 2015 3.5 Theranostics: Fastest Growing Segment of the CDx Market 3.6 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2016-2026 3.7 Drivers 3.7.1 Stakeholders in the Companion Diagnostics Market 3.7.2 Regulatory Authorities 3.7.3 Payers 3.7.4 Partnerships 3.8 Restraints 3.8.1 Competitive Landscape 3.8.2 Testing Laboratories 3.8.3 Physicians and Patients
4. Leading US-Based Companion Diagnostic Companies, 2016 4.1 Abbott Laboratories, Inc. 4.1.1 Abbott Laboratories: Financial Overview 4.1.2 Companion Diagnostics Product Portfolio 4.1.2.1 Vysis ALK Break Apart FISH Probe Kit 4.1.2.2 PathVysion HER-2 DNA Probe Kit 4.1.3 Companion Diagnostics in Pipeline 4.1.4 Recent Activity and Collaborations 4.1.4.1 Collaboration with Merck 4.1.4.2 Collaborative Efforts with Idera 4.1.4.3 Collaboration with AstraZeneca 4.2 Myriad Genetics 4.2.1 Myriad Genetics: Financial Overview 4.2.2 Myriad Genetics: Companion Diagnostics Product Portfolio 4.2.2.1 myRisk Hereditary Cancer Test 4.2.2.2 BRACAnalysis® 4.2.2.3 CCP Assay 4.2.2.4 PREZEON™ 4.2.3 Myriad Genetics: Companion Diagnostics Pipeline 4.2.3.1 HRD Assay 4.2.4 Myriad Genetics: Companion Diagnostics Collaborations: 4.2.4.1 Myriad/AstraZeneca: Premarket Approval Application 4.2.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market 4.2.4.3 Myriad/ TESARO Companion Collaboration 4.2.4.4 Collaboration with AbbVie 4.2.4.5 Agilent/Bristol-Myers Squibb 4.3 Genomic Health 4.3.1 Genomic Health: Financial Overview 4.3.2 Genomic Health: Companion Diagnostics Product Portfolio 4.3.2.1 Oncotype Dx Portfolio 4.3.2.2 Oncotype SEQ 4.3.3 Genomic Health: Companion Diagnostics in Pipeline 4.3.3.1 RxPonder Trial 4.3.4 Genomic Health: Collaborations & Partnerships 4.3.4.1 Partnership with OncoMed 4.3.4.2 Genomic Health Partners with Epic Sciences 4.4 Thermo Fisher Scientific – Life Technologies 4.4.1 Thermo Fisher: Financial Overview 4.4.2 Thermo Fisher: Geographic Segmentation 4.4.3 Recent Collaborations and Acquisitions 4.4.3.1 Acquisition of Life Technologies 4.4.3.2 Acquisition of Prionics 4.4.3.3 Acquisition of Advanced Scientifics, Inc. 4.4.3.4 Acquisition of Alfa Aesar 4.4.3.5 Affymetrix: Thermo Fisher’s Next Target 4.4.3.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing 4.4.3.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono 4.4.3.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC 4.5 Johnson & Johnson 4.5.1 Johnson & Johnson: Financial Overview 4.5.2 Johnson & Johnson Division by Region 4.5.3 Johnson & Johnson: Companion Diagnostics Portfolio 4.5.3.1 Companion Diagnostics Center of Excellence 4.5.4 Johnson & Johnson: Companion Diagnostics Partnerships 4.5.4.1 Collaboration with Tianjin Medical University Cancer Institute and Hospital 4.5.4.2 Partnership with Massachusetts General Hospital 4.5.4.3 Partnership with Biocartis 4.6 Laboratory Corporation of America (LabCorp) 4.6.1 LabCorp: Financial Overview 4.6.2 LabCorp Companion Diagnostics Portfolio 4.6.3 Recent M&A Activity and Other Key Developments 4.6.3.1 Agreement with Medco Health Sciences 4.6.3.2 Non-Exclusive License Agreement with Merck 4.6.3.3 Acquisition of Monogram Biosciences 4.6.3.4 Acquisition of Genzyme Genetics 4.6.3.5 Partnership with ARCA Biopharma 4.7 Illumina 4.7.1 Illumina: Financial Overview 4.7.2 Illumina: Companion Diagnostics Product Portfolio 4.7.2.1 MiSeqDx™ System 4.7.3 Illumina: Recent Activity & Collaborations 4.7.3.1 AstraZeneca Partners with Illumina 4.7.3.2 bioMérieux Collaborates with Illumina
5. Leading European Companion Diagnostic Companies, 2016 5.1 Roche: Global Diagnostics Leader 5.1.1 Ventana Medical Systems (Roche) 5.1.2 Roche: Financial Overview 5.1.3 Roche Diagnostics Geographic Segmentation 5.1.4 Roche’s Collaborations and Recent Activity 5.1.5 Roche Diagnostics: Companion Diagnostics Product Portfolio & Pipeline 5.1.6 Ventana Companion Diagnostics: Robust New Prototype Assays 5.1.7 Recent Companion Diagnostic External Collaborations 5.1.7.1 Foundation Medicine and Roche Collaborate 5.1.7.2 Ventana Partners with Genmab 5.1.7.3 Ferring Collaborates with Roche for CDx Development for Infertility Treatment 5.1.7.4 MedImmune Partners with Ventana 5.1.7.5 Merck Enters Agreement with Ventana 5.1.7.6 AstraZeneca and Roche Partnership 5.1.7.7 Boehringer Ingelheim Collaborate with Roche 5.1.7.8 ImmunoGen Enter Agreement with Ventana 5.1.8 Roche Diagnostics: Major M&A Activity and Strategic Partnerships 5.1.8.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities 5.1.8.2 IQuum Acquisition Allows Movement into POC MDx Market 5.1.8.3 Seragon Acquisition Strengthens Leading Position in Oncology 5.1.8.4 Santaris Acquisition Enhances Roche’s Position in RNA-Targeted Drugs Market 5.1.8.5 Bina Acquisition Brings Big Data Solution to Support NGS Development 5.1.8.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio 5.1.8.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio 5.1.8.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology 5.1.8.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities 5.1.8.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader 5.2 Qiagen 5.2.1 Qiagen: Financial Overview 5.2.2 Qiagen: Geographic Segmentation 5.2.2.1 Qiagen: Companion Diagnostics Collaborations 5.2.2.2 Collaboration with Eli Lilly 5.2.2.3 Collaboration with AstraZeneca 5.2.2.4 Collaboration with Astellas Pharma 5.2.2.5 Collaboration with Novartis 5.2.2.6 Collaboration with Array BioPharma 5.2.2.7 Collaboration with Protagen 5.3 Agilent Technologies (Dako) 5.3.1 Life Sciences and Diagnostics Business 5.3.2 Agilent Life Sciences and Diagnostics: Financial Overview 5.3.3 Agilent: Next Generation Sequencing Platforms 5.3.4 Recent Companion Diagnostic Collaborations 5.3.4.1 Merck and Aglient Cancer Collaborations 5.3.4.2 Pfizer and Aglient an Ongoing Collaboration 5.3.4.3 Bristol-Myers Squibb and Aglient Partnership 5.4 bioMérieux 5.4.1 bioMérieux: Financial Overview 5.4.2 Sales by Region, 2014 5.4.3 Sales by Technology, 2015 5.4.4 Companion Diagnostics: Recent M&A Activity & Collaboration 5.4.4.1 Collaboration with Gilead Sciences 5.4.4.2 Collaboration with Ipsen 5.4.4.3 Collaboration with Merck 5.4.4.4 Collaborations with GSK and Novartis 5.4.4.5 Mergers, Acquisitions and Collaborations 5.4.5 bioTheranostics: Subsidiary for Oncology Diagnostics 5.5 Siemens Healthcare 5.5.1 Siemens: Financial Overview 5.5.2 Siemens Healthcare 5.5.3 Siemens Diagnostics 5.5.4 Outperforming the Market 5.5.5 Companion Diagnostics 5.5.5.1 Partnership with Pfizer 5.5.5.2 Partnership with ViiV Healthcare 5.5.5.3 Partnership with Tocagen 5.6 MDxHealth 5.6.1 MDxHealth: Financial Overview 5.6.2 Companion Diagnostics 5.6.2.1 PharmacoMDx 5.6.2.2 PredictMDx for Brain Cancer 5.6.2.3 PredictMDx for Colon Cancer 5.6.3 R&D Capabilities 5.6.4 Recent Collaborations and Partnerships 5.6.4.1 Cerba HealthCare Belgium Collaboration 5.6.4.2 SouthGenetics Partnership 5.6.4.3 Sumitomo Sign Pharmaco Partnership for Japan 5.6.4.4 Partnership with GSK
6. Leading Rest of the World Companion Diagnostic Companies, 2016 6.1 MedGenome 6.1.1 MedGenome: Companion Diagnostics Product Portfolio 6.1.1.1 Integrated Genomics Platform 6.1.1.2 OncoPept 6.1.1.3 OncoMD 6.1.1.4 Next-Generation Sequencing Informatics 6.2 Diagnocure 6.2.1 Diagnocure Products 6.2.1.1 Gene Expression and Copy Number Variation (CNV) Analysis 6.2.1.2 Mutation Detection 6.2.1.3 SNP Genotyping 6.2.1.4 Platform and Laboratory Environment 6.2.2 DiagnoCure Collaborations and Partnerships 6.3 Seegene Inc. 6.3.1 Seegene: Product Portfolio 6.3.1.1 MuDT™(Multiple Detection Temperatures) Technology 6.3.1.2 TOCE™ Technology 6.3.1.3 DPO™ Technology 6.3.1.4 READ Technology 6.3.1.5 ACP™ Technology 6.3.2 Seegene Collaborations and Partnerships 6.4 Savyon Diagnostics 6.4.1 Savyon: Product Portfolio 6.4.1.1 NanoCHIP® 6.4.2 Savyon Diagnostics Product Lines 6.4.3 Savyon Diagnostics Services 6.5 Other Leading Companion Diagnostics Partnerships
7. Research Interview 7.1 Dr Ramprasad, Chief Operating Officer, and Mr Hiranjith G H, Director, Corporate Planning, MedGenome 7.1.1 MedGenome Overview 7.1.2 CDx Portfolio at MedGenome 7.1.3 MedGenome’s Competitive Advantage 7.1.4 Future Directions For MedGenome and the Industry
8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026 8.1 SWOT Analysis of the Companion Diagnostics Market, 2016-2026 8.1.1 Strengths 8.1.1.1 A CDx Strategy Decreases the Length of Approval Process 8.1.1.2 Premium Prices for Companion Diagnostics 8.1.1.3 A CDx Development Strategy Can Generate More Effective Drugs 8.1.1.4 Therapeutics Tied with CDx can have Safer Profiles 8.1.1.5 Reducing the Cost of Healthcare 8.1.1.6 Increased Regulatory Scrutiny on Marketed Drugs 8.1.1.7 Targeted Therapies Will Drive the CDx Market 8.1.2 Weaknesses 8.1.2.1 Reimbursement Challenges 8.1.2.2 Lack of Clear Regulatory Guidelines 8.1.2.3 Capital Intensity is High 8.1.3 Opportunities 8.1.3.1 Fast-growing Emerging Markets 8.1.3.2 Next Generation Sequencing 8.1.3.3 Many New CDx/ Pharma Company Partnerships 8.1.4 Threats 8.1.4.1 Complex Business Models and Business Partnerships 8.1.4.2 Medical Device Excise Tax 8.2 STEP Analysis of the Companion Diagnostics Market, 2016-2026 8.2.1 Social Factor: Raising Awareness will Lead to Greater Product Adoption 8.2.2 Technologically Innovation Driven – Growing Manufacturing Efficiency 8.2.3 Economic Potential: Emerging Markets Create Demand 8.2.4 Political Issues: Government Influence
9. Conclusions from Our Research and Analysis 9.1 Overview 9.2 Theranostics: A Fast Growing Market 9.3 Leading Companion Diagnostic Companies 9.4 Pharmaceutical/Diagnostic Partnership Model 9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics 9.6 Commercial Drivers of the Companion Diagnostics Market 9.7 Commercial Restraints of the Companion Diagnostics Market 9.8 Concluding Remarks
List of Tables Table 2.1 Differences Between Traditional & Personalised Medicine, 2016 Table 2.2 Technologies and Platforms for Biomarker Research, 2016 Table 2.3 Examples of Clinically Relevant Cancer Biomarkers, 2016 Table 3.1 The World IVD Market: Main Segment Revenue Shares ($bn), 2015 Table 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2020 Table 3.3 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026 Table 3.4 CDx Market Share (%) in the IVD Market, 2014, 2020, 2026 Table 4.1 Abbott Laboratories: Company Overview, 2016 Table 4.2 Abbott Laboratories: Historical Revenue ($bn), 2012-2015 Table 4.3 Abbott Laboratories: Biomarkers Pipeline, 2016 Table 4.4 Myriad Genetics: Company Overview, 2016 Table 4.5 Genomic Health: Company Overview, 2016 Table 4.6 Thermo Fisher Scientific: Revenue Sales ($bn), by Business Sector, 2012-2015 Table 4.7 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2013-2015 Table 4.8 Johnson & Johnson: Revenues ($bn) and Shares (%) by Sector, 2015 Table 4.9 Johnson & Johnson: Revenues ($bn) by Sector, 2015 Table 4.10 Johnson & Johnson: Revenue ($bn) and Shares (%) by Region, 2015 Table 4.11 LabCorp: Revenues ($bn) and Shares (%) by Business Segment, 2015 Table 4.12 Selected List of LabCorp’s Portfolio of Companion Diagnostics, 2016 Table 4.13 Selected List of LabCorp’s Portfolio of Companion Diagnostics, 2016 Table 5.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014 Table 5.2 Roche Diagnostics: Major Companion Diagnostic Projects, 2015 Table 5.3 Roche Diagnostics: List of Marketed Companion Diagnostics, 2015 Table 5.4 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2010-2015 Table 5.5 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2012-2015 Table 5.6 Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015 Table 5.7 bioMérieux: Revenue ($bn) and AGR (%), 2010-2015 Table 5.8 bioMérieux: Revenue ($bn) and Revenue Change (%) by Region, 2014-2015 Table 5.9 bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2014-2015 Table 5.10 Siemens Diagnostics: Ranking (#) by Sector, 2016 Table 5.11 MDxHealth: Companion Diagnostics Pipeline, 2016 Table 6.1 Other Leading Companion Diagnostics Partnerships, 2016 Table 6.2 List of Other Companies in the Companion Diagnostics Market, 2016 Table 6.3 List of Other Companies in the Companion Diagnostics Market, 2016
List of Figures Figure 1.1 Companion Diagnostics Market Segmentation, 2016 Figure 2.1 The Pillars of Personalised Medicine Figure 2.2 Type of Companion Diagnostics on the Basis of Application, 2016 Figure 3.1 The World IVD Market: Main Segment Revenue Shares (%), 2015 Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Figure 3.3 The World CDx Market Share (%) in the IVD Market, 2020 Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2026 Figure 4.1 Thermo Fisher Scientific: Revenue Sales ($bn), by Business Sector, 2015 Figure 4.2 Thermo Fisher Scientific: Revenue Share (%) by Geography, 2015 Figure 4.3 Johnson & Johnson: Revenues ($bn) by Sector, 2015 Figure 4.4 Johnson & Johnson: Revenue Shares (%) by Sector, 2015 Figure 4.5 Johnson & Johnson: Revenue Shares (%) by Region, 2015 Figure 4.6 Johnson & Johnson: Revenue Share (%) for US, 2015 Figure 4.7 LabCorp: Revenues ($bn) by Business Segment, 2015 Figure 4.8 LabCorp: Revenue Shares (%) by Business Segment, 2015 Figure 5.1 Roche Diagnostics: Revenue ($bn) by Business Area, 2014 Figure 5.2 Roche Diagnostics: Revenue (%) by Business Area, 2014 Figure 5.3 Roche Diagnostics: Revenue (%) by Geography, 2014 Figure 5.4 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2015 Figure 5.5 Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015 Figure 5.6 bioMérieux: Revenue ($bn) by Region, 2015 Figure 5.7 bioMérieux: Revenue Share (%) by Technology, 2015 Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2016-2026
Abbott Laboratories AbbVie Alere ARCA Biopharma ARGENE AstraZeneca Bayer Beckman Coulter BioMarin Pharmaceutical bioMérieux Biocartis Biomonitor Boehringer Ingelheim Brain Resource Company Bristol-Myers Squibb CancerGuide Diagnostics Caprion Proteomics Caris Life Sciences Celldex Therapeutics Cellestis Cephalon Cepheid Clearstone Central Laboratories Clinical Reference Laboratory CompanDX Compendia Bioscience Crescendo Bioscience Curidium Medica Dako DiagnoCure DxS Eli Lilly Endocyte Epitomics Exosome Diagnostics Explera Flagship Biosciences Foundation Medicine Genfit GenMark Diagnostics Genomic Health Genzyme Genetics GlaxoSmithKline HistologiX Hologic Ibis Biosciences InDex Pharmaceuticals Invivoscribe Technologies Ipsen Ipsogen Johnson & Johnson Knome Lab21 LabCorp Laboratory for Personalized Molecular Medicine Life Technologies MDxHealth Medco Health Sciences MedGenome Merck MolecularMD Monogram Biosciences Myriad Genetics Nanosphere Navigenics Oncomed Opko Health Oxford BioTherapeutics Pfizer PharmaMar Progenika Biopharma Prometheus QIAGEN Quest Diagnostics Quintiles Transnational Corporation Randox Pharma Services RiboMed Biotechnologies Roche SABioscience Corporation Saladax Biomedical Siemens Signal Genetics Sirius Genomics Skyline Diagnostics STARLIMS Technologies SterilMed Synthes Takeda Target Discovery TcLand Expression Theranostics (NZ) Theranostics Health TIB MolBiol Tocagen Tragara Pharmaceuticals Transgene Transgenomic TrimGen Corporation Unilabs
Download sample pages
Complete the form below to download your free sample pages for Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
Download sample pages
Complete the form below to download your free sample pages for Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
